Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.

Thumbnail Image
View / Download1.14 MB

Date

2017-12

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

181
views
205
downloads

Citation Stats

Abstract

Type

Journal article

Department

Description

Provenance

Subjects

Adverse events, DNA repair, PARP inhibitors, Secondary malignancy, Treatment-related leukemia

Citation

Permalink

https://hdl.handle.net/10161/17206

Published Version (Please cite this version)

10.1016/j.clgc.2017.07.005

Publication Info

Zhu, Jason, Matthew Tucker, Endi Wang, Joel S Grossman, Andrew J Armstrong, Daniel J George and Tian Zhang (2017). Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 15(6). pp. e1137–e1141. 10.1016/j.clgc.2017.07.005 Retrieved from https://hdl.handle.net/10161/17206.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Scholars@Duke

Armstrong

Andrew John Armstrong

Professor of Medicine

I am a clinical and translational investigator focused on precision therapies and biomarkers in advanced prostate and other GU cancers.  I oversee a large research team of clinical and lab based investigators focused on improving patient outcomes, preventing metastatic disease, and understanding the biology of aggressive prostate cancer.  Some key themes:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. Developing prognostic and predictive models for progression and survival in metastatic prostate cancer
7. Examining surrogate markers of mortality in metastatic prostate cancer
8. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

George

Daniel James George

Eleanor Easley Distinguished Professor in the School of Medicine
Zhang

Tian Zhang

Adjunct Associate Professor in the Department of Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.